Literature DB >> 19208347

Spontaneous increases in alanine aminotransferase levels in asymptomatic chronic hepatitis B virus-infected patients.

Manoj Kumar1, Ranjit Chauhan, Nitin Gupta, Syed Hissar, Puja Sakhuja, Shiv K Sarin.   

Abstract

BACKGROUND & AIMS: No information is available about the frequency or factors that predict spontaneous increases in alanine aminotransferase (ALT) levels in asymptomatic Indian patients with chronic hepatitis B virus (HBV) infection who are HB e antigen (HBeAg) negative and have normal ALT levels.
METHODS: We followed 217 asymptomatic patients with chronic HBV who were HBeAg negative, anti-HBe antigen (anti-HBe) positive, and had normal ALT levels. Spontaneous increases in ALT levels (ALT flares) were considered to be >2-fold the upper limit of normal (ULN) and were accompanied by HBV DNA levels>or=10(5) copies/mL or a 100-fold increase from the previously measured level.
RESULTS: During a median follow-up period of 69.0 months, spontaneous ALT flares occurred in 43 patients (an annual rate of 4.3%), with cumulative probabilities of 10.8% and 47.3% after 5 and 10 years, respectively. Based on multinomial logistic regression, the probability of an ALT flare correlated with age>or=30 years at presentation (odds ratio [OR], 5.31; 95% confidence interval [CI]: 1.53-18.39; P=.008), male sex (OR, 4.54; 95% CI: 1.01-20.76; P=.05), and presence of a precore mutation (OR, 10.99; 95% CI: 3.67-32.92; P<.001). The median time to spontaneous ALT flare after enrollment was 25 months (range, 1-128 months; 10th percentile=3.4 months).
CONCLUSIONS: In asymptomatic patients with chronic HBV infection who have normal ALT levels and are HBeAg negative, the annual rate of ALT flares was 4.3%. Precore mutants, male sex, and age>or=30 years at presentation are independent predictors for an ALT flare. A follow-up every 3 months can capture up to 90% of flares and would help identify patients who require antiviral therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19208347     DOI: 10.1053/j.gastro.2009.01.011

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  17 in total

Review 1.  Acute exacerbation of chronic hepatitis B: the dilemma of differentiation from acute viral hepatitis B.

Authors:  Pankaj Puri
Journal:  J Clin Exp Hepatol       Date:  2013-10-17

2.  Chronic hepatitis B: the demise of the 'inactive carrier' phase.

Authors:  Apostolos Koffas; Manoj Kumar; Upkar S Gill; Ankur Jindal; Patrick T F Kennedy; S K Sarin
Journal:  Hepatol Int       Date:  2021-02-27       Impact factor: 6.047

3.  Host genetic variants and hepatitis B virologic features in HBeAg-negative hepatitis B carriers with long-term biochemical remission.

Authors:  Chih-Lin Lin; Tai-Chung Tseng; Tung-Hung Su; Chun-Jen Liu; Pei-Jer Chen; Ming-Yang Lai; Ding-Shinn Chen; Jia-Horng Kao
Journal:  Hepatol Int       Date:  2011-07-21       Impact factor: 6.047

4.  Circulating Tregs correlate with viral load reduction in chronic HBV-treated patients with tenofovir disoproxil fumarate.

Authors:  Nirupma TrehanPati; Shyam Kotillil; Syed S Hissar; Shikha Shrivastava; Arshi Khanam; Sukriti Sukriti; Siddartha K Mishra; Shiv Kumar Sarin
Journal:  J Clin Immunol       Date:  2011-02-09       Impact factor: 8.317

5.  Combination and evolution of HBV mutant strains in the HBeAg-positive status predict clinical outcomes after HBeAg seroconversion.

Authors:  Chien-Hung Chen; Chuan-Mo Lee; Jing-Houng Wang; Tsung-Hui Hu; Chao-Hung Hung; Chi-Sin Changchien; Sheng-Nan Lu
Journal:  Hepatol Int       Date:  2012-06-21       Impact factor: 6.047

6.  Naturally occurring core immune-escape and carboxy-terminal mutations\truncations in patients with e antigen negative chronic hepatitis B.

Authors:  Ranjit Chauhan; Shiv K Sarin; Manoj Kumar; Jayashree Bhattacharjee
Journal:  Hepatol Int       Date:  2011-12-02       Impact factor: 6.047

7.  Combining the HBsAg decline and HBV DNA levels predicts clinical outcomes in patients with spontaneous HBeAg seroconversion.

Authors:  Shih-Cheng Yang; Sheng-Nan Lu; Chuan-Mo Lee; Tsung-Hui Hu; Jing-Houng Wang; Chao-Hung Hung; Chi-Sin Changchien; Chien-Hung Chen
Journal:  Hepatol Int       Date:  2012-06-22       Impact factor: 6.047

8.  Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.

Authors:  S K Sarin; M Kumar; G K Lau; Z Abbas; H L Y Chan; C J Chen; D S Chen; H L Chen; P J Chen; R N Chien; A K Dokmeci; Ed Gane; J L Hou; W Jafri; J Jia; J H Kim; C L Lai; H C Lee; S G Lim; C J Liu; S Locarnini; M Al Mahtab; R Mohamed; M Omata; J Park; T Piratvisuth; B C Sharma; J Sollano; F S Wang; L Wei; M F Yuen; S S Zheng; J H Kao
Journal:  Hepatol Int       Date:  2015-11-13       Impact factor: 6.047

Review 9.  Transaminase Elevations during Treatment of Chronic Hepatitis B Infection: Safety Considerations and Role in Achieving Functional Cure.

Authors:  Andrew Vaillant
Journal:  Viruses       Date:  2021-04-23       Impact factor: 5.048

10.  Gender Differences Among Patients Hospitalized With Cirrhosis in the United States.

Authors:  Jessica B Rubin; Vinay Sundaram; Jennifer C Lai
Journal:  J Clin Gastroenterol       Date:  2020-01       Impact factor: 3.174

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.